



Forbion Capital Partners co-leads \$24m Series C Financing of Mitralign

Naarden, December 3, 2007 Forbion Capital Partners today announced the closure of \$24M Series C financing round for catheter development company Mitralign. The investment falls under Forbion's focus on interventional cardiology technologies. This financing will enable the Company to complete its initial clinical research and obtain CE Mark approval of the Mitralign System. This round, co-led by Medtronic [NYSE: MDT] and the Johnson & Johnson Development Corporation, also includes Oakwood Medical, Palisades Capital and Accelerated Technology Partners. Existing investors Giza, Oxford Biosciences and Triathlon Medical Venture Partners also participated in the round.

Forbion Capital Partners General Partner Martien van Osch will remain an active member of the Board of Directors and commented: "The unprecedented interest from strategic players in Mitralign highlights its unique position in the mitral valvular space. Mimicking the surgical procedure in a percutaneous setting is a way to success in this field."

Mitralign President & Chief Executive Officer John MacMahon stated, "This financing will allow us to advance our endeavour to emulate surgical precision with a catheter-based approach for mitral valve repair."

To date the Company has enrolled over 20 patients in a catheter study with Dr. Adrian Ebner in Asuncion, Paraguay. The Company will proceed with the addition of clinical sites for the Mitralign Pilot Study in Europe. These additional sites will include electrophysiology (EP) centers to join pre-eminent interventional cardiology (IC) sites such as Prof. Dr. med. Eberhard Grube, Helios Heart Center, Siegburg, Germany. Dr. Grube believes, "The Mitralign device is well suited for an integrated approach of the skills and techniques of both the EP and IC. All of our patients will be served best by this collaboration."

-ENDS-

About mitral valve regurgitation

Mitral valve regurgitation is a common condition in patients suffering Congestive Heart Failure (CHF), a disease affecting 25 million patients worldwide. Clinical studies have proven mitral valve regurgitation significantly increases the risk of mortality in patients afflicted with CHF, and recommend earlier mitral valve regurgitation treatment in CHF patients.

About Mitralign - www.mitralign.com

Combining surgical precision with interventional therapy, Mitralign is developing an innovative, catheter-based method to effectively treat mitral valve regurgitation in patients suffering from Congestive Heart Failure. Mitralign's goal is to emulate the technique employed in traditional open heart surgical repair but in a far less invasive manner.

About Forbion Capital Partners – www.forbion.com

Forbion Capital Partners invests in EU and US Life Sciences companies, developing world-class products and technologies. The Forbion team has invested in 38 drug development and med tech companies since 2000, initially as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank NV. In December of 2006 the group became independent by broadening its investor base and changing its name to Forbion Capital Partners. In recent years, the Forbion team has successfully divested from 13 portfolio companies, leaving an active portfolio of 25 companies. Assets under management currently exceed €200 M.

For more information, please contact:

Media:

College Hill Life Sciences

Adam Michael / Justine Lamond

Ph: +44 (0)20 7866 7857

forbion@collegehill.com

Forbion Capital Partners:

Managing Partner Bart Bergstein,

Bart.bergstein@forbion.com

General Partner Martien van Osch,

Martien.van.osch@forbion.com

Ph: +31 3 5699 3000

Mitralign

COO/CFO Richard J. Omilanowicz,

Ph: +1 978-863-2404

romilanowicz@mitralign.com